Table 2. The evaluation of trastuzumab-related cadiotoxicity by variable factors.

Variables		Δ EF 10–20% 〔n(%)〕	Δ EF >20% or EF <50% 〔n(%)〕	CHF need medication 〔n(%)〕	CHF need ICU or intubation 〔n(%)〕	P value
Trastuzumab	Q3W	13(8.2)	2(1.3)	3(1.9)	3(1.9)	0.913
	QM	11(10.7)	2(1.9)	2(1.9)	1(1.0)
Chemotherapy	Other	2(7.7)	0(0)	1(3.8)	0(0)	0.943
	Taxane*	2(4.4)	1(2.2)	0(0)	0(0)
	Epirubicin	1(6.7)	0(0)	0(0)	0(0)
	Doxorubicin	6(14.6)	1(2.4)	1(2.4)	1(2.4)
	Epirubicin +Taxane	3(7.0)	1(2.3)	1(2.3)	0(0)
	Doxorubicin + Taxane	10(11.0)	1(1.1)	2(2.2)	3(3.3)
Stage	Stage I	6(12.0)	2(4.0)	0(0)	0(0)	0.649
	Stage IIA	5(8.6)	0(0)	0(0)	0(0)
	Stage IIB	4(12.9)	0(0)	1(3.2)	2(6.5)
	Stage IIIA	3(12.0)	1(4.0)	1(4.0)	1(4.0)
	Stage IIIB	1(9.1)	0(0)	0(0)	0(0)
	Stage IIIC	0(0)	1(5.9)	1(5.9)	0(0)
	Stage IV	5(7.5)	0(0)	2(3.0)	1(1.5)
Side	Right	12(9.8)	0(0)	1(0.8)	2(1.6)	0.224
	Left	12(9.2)	4(3.1)	3(2.3)	2(1.5)
	Bilateral	0(0)	0(0)	1(12.5)	0(0)
Age (years)	<55	18(11.5)	3(1.9)	0(0)	3(1.9)	0.032
	> = 55	6(5.7)	3(1.0)	3(4.8)	1(1.0)
Hypertension	With	3(6.1)	2(4.1)	2(4.1)	1(2.0)	0.310
	Without	21(9.9)	2(0.9)	3(1.4)	3(1.4)
Diabetes	With	2(10.0)	0(0)	1(5.0)	0(0)	0.782
	Without	22(9.2)	4(1.7)	4(1.7)	4(1.7)
Smoke	With	1(7.7)	0(0)	0(0)	0(0)	0.940
	Without	23(9.3)	4(1.6)	5(2.0)	4(1.6)
Hyperlipidemia	With	0(0)	0(0)	1(12.5)	0(0)	0.213
	Without	24(9.5)	4(1.6)	4(1.6)	4(1.6)
Radiotherapy	With	13(8.2)	2(1.3)	4(2.5)	3(1.9)	0.821
	Without	10(10.4)	2(2.1)	1(1.0)	1(1.0)

EF = ejection fraction; n = number; CHF = congestive heart failure; ICU = intensive care unit

* Taxane included docetaxel and paclitaxel